Drug Trial Radar · NCT03502668
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Jul 27, 2018
Primary completion
Jan 13, 2026
Study completion Jan 13, 2026
Sponsor
- Lead sponsor
- Taiho Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic response in subjects with International Prognostic Scoring System (IPSS) risk category of low-risk or Intermediate-1 MDS. This study will be conducted in two phases. In phase 1 subjects will be randomized into 3 cohorts in a 28-day cycles. Phase 2, 80 new subjects will be randomized in a 1:1 ratio into 2 doses/schedules.
Conditions
- Myelodysplastic Syndromes
Interventions
ASTX727 LDDrug
oral decitabine (LD) + cedazuridine (E7727)
ASTX727 SDDrug
oral decitabine (SD) + cedazuridine (E7727)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of drug-related Grade ≥3 Adverse Events (AEs) or dose-limiting toxicities (DLTs) (if any) for each cohort dose/scheduleTime frame: 18-24 months
- Hematologic response based on normalization of conversion of any baseline cytopenia or anemia (hemoglobin response, neutrophil response, platelet response, transfusion independence)Time frame: 18-24 months
Locations
29 sites in 6 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama
University of Colorado, Anschutz Cancer Pavilion
Aurora, Colorado
Yale Cancer Center
New Haven, Connecticut
Mayo Clinic Florida
Jacksonville, Florida
BRCR Medical Center Inc.
Plantation, Florida
Moffitt Cancer Center Site#507
Tampa, Florida
The University of Chicago
Chicago, Illinois
Indiana University Health Hospital - Simon Cancer Center
Indianapolis, Indiana
University of Kansas Clinical Research Center
Westwood, Kansas
The Center for Cancer and Blood Disorders (RCCA MD LLC - Maryland Division)
Bethesda, Maryland
Mayo Clinic
Rochester, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Oregon Health and Science University Knight Cancer Institute
Portland, Oregon
Sarah Cannon Research Institute
Nashville, Tennessee
Vanderbilt University Medical Center - Hematology-Oncology
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Texas Oncology - Tyler
Tyler, Texas
ZNA - Campus Middelheim
Antwerp, Belgium
Az St-Jan Brugge-Oostende A.V.
Bruges, Belgium
University of Alberta Hospital - Hematology Research
Edmonton, Canada
London Regional Cancer Center
London, Ontario, Canada
Universitaetsklinikum Freiburg Site#703
Freiburg im Breisgau, Germany
Universitätsklinikum Halle
Halle, Germany
Universita degli Studi di Firenze
Florence, Italy
Hospital Universitario Vall d Hebron
Barcelona, Spain
Institut Català d'Oncologia Badalona Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital Univeristario y Politecnico La Fe Servicio de Hematologia
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.